Association between Serum Progranulin and Cognitive Impairment in Patients with Coronary Artery Disease: A Case-Control Study.

IF 2.5 4区医学 Q3 CLINICAL NEUROLOGY

Dementia and Geriatric Cognitive Disorders Pub Date : 2026-01-01 Epub Date: 2025-07-26 DOI:10.1159/000547668

Ping Gong, Jing Shi, Kang Ye, Zhongsheng Zhu

{"title":"Association between Serum Progranulin and Cognitive Impairment in Patients with Coronary Artery Disease: A Case-Control Study.","authors":"Ping Gong, Jing Shi, Kang Ye, Zhongsheng Zhu","doi":"10.1159/000547668","DOIUrl":null,"url":null,"abstract":"Introduction: Progranulin (PGRN), a secreted glycoprotein, plays a crucial role in several biological processes. However, its association with cognitive impairment in patients with coronary artery disease (CAD) remains unclear. This study aimed to evaluate the relationship between serum PGRN levels and cognitive impairment in patients with CAD.Methods: A total of 177 patients with CAD and 150 non-CAD controls were included, and serum PGRN concentrations and other CAD-related risk factors were measured. Cognitive function was assessed, and logistic regression analysis was performed to identify the predictors of mild cognitive impairment (MCI).Results: In a comparison between patients with CAD (n = 177) and non-CAD (n = 150), CAD with MCI (n = 64), and CAD without MCI (n = 113), patients with CAD and CAD with MCI had significantly lower levels of PGRN (94.99 ± 11.23 ng/mL and 89.41 ± 9.53 ng/mL) than those of non-CAD and CAD without MCI (127.64 ± 14.06 ng/mL and 98.15 ± 10.92 ng/mL, respectively). Multivariate analysis revealed that lower PGRN levels (odds ratio [OR] = 0.937, 95% confidence interval [CI] = 0.897-0.979; p = 0.004) and elevated levels of high-sensitivity C-reactive protein (OR = 9.525, 95% CI = 1.485-61.098; p = 0.017), tumor necrosis factor-alpha (OR = 1.257, 95% CI = 1.107-1.427; p < 0.001), and transforming growth factor-beta 1 (OR = 1.153, 95% CI = 1.036-1.284; p = 0.009) were independent risk factors for MCI. Conversely, higher brain-derived neurotrophic factor levels were protective (OR 0.809, 95% CI = 0.734-0.892; p < 0.001). Receiver operating characteristic analysis identified a PGRN cutoff of 93.52 ng/mL as predictive of MCI risk in patients with CAD.Conclusion: These findings suggest that reduced serum PGRN levels are associated with cognitive impairment in CAD, highlighting their potential role as biomarkers.","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"95-105"},"PeriodicalIF":2.5000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dementia and Geriatric Cognitive Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547668","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Progranulin (PGRN), a secreted glycoprotein, plays a crucial role in several biological processes. However, its association with cognitive impairment in patients with coronary artery disease (CAD) remains unclear. This study aimed to evaluate the relationship between serum PGRN levels and cognitive impairment in patients with CAD.

Methods: A total of 177 patients with CAD and 150 non-CAD controls were included, and serum PGRN concentrations and other CAD-related risk factors were measured. Cognitive function was assessed, and logistic regression analysis was performed to identify the predictors of mild cognitive impairment (MCI).

Results: In a comparison between patients with CAD (n = 177) and non-CAD (n = 150), CAD with MCI (n = 64), and CAD without MCI (n = 113), patients with CAD and CAD with MCI had significantly lower levels of PGRN (94.99 ± 11.23 ng/mL and 89.41 ± 9.53 ng/mL) than those of non-CAD and CAD without MCI (127.64 ± 14.06 ng/mL and 98.15 ± 10.92 ng/mL, respectively). Multivariate analysis revealed that lower PGRN levels (odds ratio [OR] = 0.937, 95% confidence interval [CI] = 0.897-0.979; p = 0.004) and elevated levels of high-sensitivity C-reactive protein (OR = 9.525, 95% CI = 1.485-61.098; p = 0.017), tumor necrosis factor-alpha (OR = 1.257, 95% CI = 1.107-1.427; p < 0.001), and transforming growth factor-beta 1 (OR = 1.153, 95% CI = 1.036-1.284; p = 0.009) were independent risk factors for MCI. Conversely, higher brain-derived neurotrophic factor levels were protective (OR 0.809, 95% CI = 0.734-0.892; p < 0.001). Receiver operating characteristic analysis identified a PGRN cutoff of 93.52 ng/mL as predictive of MCI risk in patients with CAD.

Conclusion: These findings suggest that reduced serum PGRN levels are associated with cognitive impairment in CAD, highlighting their potential role as biomarkers.

查看原文本刊更多论文

冠状动脉疾病患者血清PGRN与认知功能障碍的关系：一项病例对照研究

前颗粒蛋白（PGRN）是一种分泌糖蛋白，在许多生物过程中起着至关重要的作用。然而，其与冠状动脉疾病（CAD）患者认知功能障碍的关系尚不清楚。本研究旨在评估冠心病患者血清PGRN水平与认知功能障碍的关系。方法：共纳入177例CAD患者和150例非CAD对照，测定血清PGRN浓度及其他CAD相关危险因素。评估认知功能，并进行逻辑回归分析以确定轻度认知障碍（MCI）的预测因素。结果：在CAD（177例）与非CAD（150例）、CAD合并MCI（64例）和CAD不合并MCI（113例）患者的比较中，CAD和CAD合并MCI患者的PGRN水平（94.99±11.23 ng/mL）和（89.41±9.53 ng/mL）显著低于非CAD和不合并MCI的CAD（127.64±14.06 ng/mL）和（98.15±10.92 ng/mL）。多因素分析显示PGRN水平较低(OR = 0.937, 95% CI = 0.897-0.979；P = 0.004)和高敏c反应蛋白（hs-CRP）水平升高(OR = 9.525, 95% CI = 1.485-61.098；P = 0.017)，肿瘤坏死因子α (TNF-α) (OR = 1.257, 95% CI = 1.107 ~ 1.427；P < 0.001)，转化生长因子-β1 (TGF-β1) (OR = 1.153, 95% CI = 1.036-1.284；P = 0.009)是MCI的独立危险因素。相反，较高的脑源性神经营养因子（BDNF）水平具有保护作用(OR 0.809, 95% CI = 0.734-0.892；P < 0.001)。受试者工作特征（ROC）分析确定PGRN截止值为93.52 ng/mL，可预测CAD患者的MCI风险。结论：这些研究结果表明，血清PGRN水平降低与CAD患者的认知功能障碍有关，突出了其作为生物标志物的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dementia and Geriatric Cognitive Disorders 医学-精神病学

CiteScore

4.70

自引率

0.00%

发文量

审稿时长

2 months

期刊介绍： As a unique forum devoted exclusively to the study of cognitive dysfunction, ''Dementia and Geriatric Cognitive Disorders'' concentrates on Alzheimer’s and Parkinson’s disease, Huntington’s chorea and other neurodegenerative diseases. The journal draws from diverse related research disciplines such as psychogeriatrics, neuropsychology, clinical neurology, morphology, physiology, genetic molecular biology, pathology, biochemistry, immunology, pharmacology and pharmaceutics. Strong emphasis is placed on the publication of research findings from animal studies which are complemented by clinical and therapeutic experience to give an overall appreciation of the field.